Streamlining Dermatology Prior Authorizations with Change Healthcare Clearinghouse

The Intersection of Dermatology PA and Change Healthcare Clearinghouse

For dermatology practices, managing prior authorizations for high-cost biologics such as Dupixent, Cosentyx, Tremfya, and Skyrizi, alongside procedures like Mohs surgery, is a significant operational challenge. Change Healthcare, as a national clearinghouse, facilitates the exchange of critical healthcare transactions, including eligibility verification (HIPAA X12 270/271) and prior authorization requests (HIPAA X12 278). Klivira's platform automates the generation and submission of these X12 transactions, ensuring that complex dermatology PA requirements are met efficiently through established clearinghouse channels.

Key Dermatology PA Triggers via X12 278

• Biologics for psoriasis and psoriatic arthritis (e.g., adalimumab, secukinumab, guselkumab, risankizumab)
• Biologics for atopic dermatitis (e.g., dupilumab, tralokinumab, JAK inhibitors)
• Biologics for hidradenitis suppurativa (e.g., adalimumab, secukinumab)
• Mohs micrographic surgery for non-melanoma skin cancers in cosmetically sensitive areas
• Advanced skin cancer treatments, including immunotherapy and targeted therapies
• Home phototherapy prescriptions (e.g., narrowband UVB, PUVA, excimer laser)

Optimizing EMR and Payer Interactions for Dermatology

Klivira integrates directly with your EMR to pull necessary clinical data, linking seamlessly with Change Healthcare Clearinghouse for electronic submission. This integration ensures that prior authorization requests for dermatology are initiated with comprehensive patient data, including diagnosis codes, clinical notes, and medication histories. By leveraging standards like X12 278, Klivira facilitates direct communication with payers through Change Healthcare, reducing manual data entry and accelerating response times for critical dermatology treatments and procedures.

Critical Documentation for Dermatology Prior Authorizations

• Evidence of prior topical therapy trials for biologics, as per AAD Clinical Guidelines
• PASI, BSA, EASI, or SCORAD severity scores for psoriasis and atopic dermatitis
• Documentation of prior conventional systemic therapy (e.g., methotrexate) trials, where applicable
• TB and hepatitis screening results prior to biologic initiation
• Mohs Appropriate Use Criteria (AUC) conformance for site, tumor type, and prior treatment
• Age-appropriate criteria for specific biologic indications

Klivira's Approach to Dermatology PA with Change Healthcare

Klivira's platform addresses the specific complexities of dermatology prior authorizations by incorporating AAD-guideline-aware step-therapy logic for biologics and AUC validation for Mohs surgery. We automate the submission of these detailed requests via Change Healthcare's X12 278 clearinghouse capabilities. Furthermore, Klivira supports periodic re-authorization workflows for chronic biologic treatments and intelligently routes requests based on medical versus pharmacy benefit, ensuring compliance and maximizing approval rates for critical dermatological care.

Addressing Common Dermatology PA Challenges

Common denial reasons in dermatology PA, such as failure to document step therapy compliance for psoriasis biologics or a mismatch with Mohs AUC, are directly addressed by Klivira's guided workflow. The platform ensures all required documentation, including disease severity scores and pre-biologic screenings, is collected and accurately submitted through Change Healthcare, minimizing rejections and streamlining the path to approval. This proactive approach helps dermatology practices avoid costly delays and administrative rework.